DR HAYES: There is an adjuvant trial and it’s going to be run by SWOG and the North American Breast Cancer Group. And it’ll be sort of an end on from Ana Maria’s study, so that the RxPONDER study is going to take low recurrence or 25 or less in the 21-gene Recurrence. This study will take others who are ER-positive, and they’ll all get endocrine therapy and then with or without everolimus. And that study is in development right now. I can’t tell you specifics of it because it’s not a protocol yet.
DR LOVE: I wonder what they’re thinking about duration of everolimus?
DR HAYES: What’s the duration?
DR GONZALEZ-ANGULO: It’s one year.
DR LOVE: One year. I wonder how that’s going to be.
DR GONZALEZ-ANGULO: So that’s a key —
DR HAYES: It’s going to be tough. Neil, 20 percent of people discontinued therapy in BOLERO-2 in the combined arm. Twenty percent — in a metastatic setting — I mean, that’s almost unprecedented for a nonchemotherapy drug, even for chemotherapy. So I think in the adjuvant setting we really have a lot of work to do to figure out adherence and persistence and compliance with this drug.
DR GONZALEZ-ANGULO: Correct.
DR HAYES: So it’s a big issue.